Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  ACADIA Pharmaceuticals Inc.    ACAD

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

ACADIA Pharmaceuticals Inc. : & SUPERVALU Inc. Announcements: (NASDAQ: ACAD), (NYSE: SVU)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/22/2013 | 08:25am CEST

New York (March 22nd, 2013) - ACADIA Pharmaceuticals Inc.(NASDAQ: ACAD) announced that Jeffrey Cummings, M.D., Sc.D., Director of Cleveland Clinic Lou Ruvo Center for Brain Health, presented detailed results from ACADIA’s pivotal Phase III -020 Study with pimavanserin in patients with Parkinson’s disease psychosis at the Emerging Science session of the 65th American Academy of Neurology (AAN) Annual Meeting.

The analysis of the full data set from the Phase III -020 Study showed robust and consistent efficacy of pimavanserin across a wide array of study measures and confirmed the positive top-line results previously reported.

“The significant and consistent results observed across measures in the Phase III -020 Study are impressive and potentially very encouraging for Parkinson’s patients who suffer from the psychosis frequently associated with this disease,” said Dr. Jeffrey Cummings.

Find out if this announcement could benefit ACAD in the very short term here:

http://www.wallstreetscoop.net/market-scan/?symbol=ACAD


SUPERVALU Inc. (NYSE: SVU) announced it completed the sale of its Albertsons, Acme, Jewel-Osco, Shaw’s and Star Market stores and related Osco and Sav-on in-store pharmacies to AB Acquisition LLC, an affiliate of a Cerberus Capital Management L.P.-led investor consortium, in a stock deal valued at $3.3 billion, including $100 million in cash and $3.2 billion in debt assumption.

Operations for these banners will transfer overnight, and the new SUPERVALU will open for business on Friday as a more efficient wholesale and retail company with annual sales of approximately $17 billion.

As part of the transaction, SUPERVALU also announced that Symphony Investors, a Cerberus-led investor consortium, completed its tender offer resulting in the acquisition of 11,686,406 shares (approximately 5.475 percent of SUPERVALU’s outstanding common stock) at a purchase price of $4.00 per share in cash.

Find out more on SVU here:

http://www.wallstreetscoop.net/market-scan/?symbol=SVU


About Us:

WallStreetScoop.net issues momentum alerts on stocks that can provide gains to day traders and short-term investors. WallStreetScoop.net provides members with timely information and exclusive alerts on under-valued stocks in the United States with the potential to deliver short-term gains.

WallStreetScoop.net monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals WallStreetScoop.net is often in the know of several large investor awareness campaigns being deployed.

Timing is everything when trading small cap stocks. Gain an Edge by joining the WallStreetScoop.net newsletter and receiving alerts from a Pro-Active team of researchers. Wall Street Scoop believes traders should have a chance at successfully trading Small stocks and invites traders and investors to be part of the free membership.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.WallStreetScoop.net

Disclosure: WallStreetScoop.net is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit WallStreetScoop.Net website, for complete risks and disclosures.

Investor Alley, its employees, officers, directors, shareholders and affiliates, hold no positions in the above-mentioned stocks.

For full disclaimer visit: www.wallstreetscoop.net/disclaimer/

Contact Info:
Thomas Greene
Wall Street Scoop
[email protected]
347-905-5009


© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ACADIA PHARMACEUTICALS INC
10/18 ACADIA PHARMACEUTICALS : Institutional Investors Ramp Up Stakes In ACADIA Pharma..
10/12 ACADIA PHARMACEUTICALS : Initiates Phase III Study of Pimavanserin in Dementia-R..
10/06 ACADIA PHARMACEUTICALS : Pharma Could Rise Another 25 Percent to $50
10/05 ACADIA PHARMACEUTICALS INC. : Today's Research Reports on Trending Tickers: ACAD..
10/04 ACADIA PHARMACEUTICALS : Initiates Phase III Study of Pimavanserin in Dementia-R..
09/21 ACADIA PHARMACEUTICALS : Patent Issued for Methods for the Treatment of Parkinso..
09/21 ACADIA PHARMACEUTICALS : to Present at the Ladenburg Thalmann 2017
09/19 ACADIA PHARMACEUTICALS : to Present at the Ladenburg Thalmann 2017 Healthcare Co..
09/11 ACADIA PHARMACEUTICALS INC. : Today's Research Reports on Trending Tickers: ACAD..
08/14 Big-name U.S. hedge funds shed healthcare stocks during the rally in second-q..
More news
News from SeekingAlpha
10/16 ACADIA : A Long-Term Investment
10/10 YOUR DAILY PHARMA SCOOP : MannKind Is A Trade Not An Investment; AstraZeneca's I..
10/10 YOUR DAILY PHARMA SCOOP : Synergy's Cash Position, Flexion's Zilretta Approval, ..
10/08 3 THINGS IN BIOTECH YOU SHOULD LEARN : October 8, 2017
10/06 YOUR DAILY PHARMA SCOOP : Gilead, Some History; Biogen's Spinraza, MDCO New Data..
Financials ($)
Sales 2017 113 M
EBIT 2017 -312 M
Net income 2017 -321 M
Finance 2017 85,9 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 38,5x
EV / Sales 2018 19,4x
Capitalization 4 446 M
Chart ACADIA PHARMACEUTICALS INC
Duration : Period :
ACADIA Pharmaceuticals Inc Technical Analysis Chart | ACAD | US0042251084 | 4-Traders
Technical analysis trends ACADIA PHARMACEUTICALS INC
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Average target price 49,1 $
Spread / Average Target 35%
EPS Revisions
Managers
NameTitle
Stephen R. Davis President, Chief Executive Officer & Director
Stephen R. Biggar Chairman
James A. Nash Senior VP-Technology Development & Operations
Todd S. Young Executive VP, Chief Financial & Accounting Officer
Srdjan R. Stankovic Executive VP, Head-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ACADIA PHARMACEUTICALS INC.25.94%4 446
INCYTE CORPORATION13.96%24 054
QUINTILES IMS HOLDINGS INC35.48%22 162
LONZA GROUP59.15%19 392
CELLTRION, INC.--.--%19 297
ALNYLAM PHARMACEUTICALS, INC.206.36%10 522